Newswise — The U.S. Food and Drug Administration has approved imetelstat (RYTELO) for the treatment of certain patients with myelodysplastic syndromes, a rare form of cancer.
Amer Zeidan, MBBS, Associate Professor of Internal Medicine (Hematology) at Yale School of Medicine and senior author of a phase III clinical trial published in The Lancet, is available to discuss the new treatment.
“Few things in a clinical investigator’s career matter as much as touching the lives of many patients he will never see by getting a good drug approved,” Dr. Zeidan said.
RSS